Evidence map›Paper›PMID 42733664›Full record

ArticleClinical and translational radiation oncology2026

Quality of life and anorectal function in rectal cancer patients undergoing immunotherapy-based total neoadjuvant therapy: a comparison of organ preservation and radical surgery.

Luoxi He, Zonglin Lv, Qianyu Zhou, Ruone Xu, Kewen Hu, Siyuan Chen, Yingxuan Lin, Shuwen Li, Yujun Liu, Mingxu Yan and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Luoxi HeDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zonglin LvDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Qianyu ZhouDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Ruone XuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Kewen HuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Siyuan ChenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yingxuan LinDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shuwen LiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yujun LiuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Mingxu YanDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Lili HuangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Weiqing LuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zhiyuan ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yajie ChenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Hui ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Menglong ZhouDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Wang YangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Juefeng WanDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Ruiyan WuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Lijun ShenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shujuan ZhouDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yan WangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Jingwen WangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Ye XuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Xinxiang LiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Sanjun CaiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Zhen ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Fan XiaDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yaqi WangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Immunotherapy-based total neoadjuvant therapy (iTNT) improves clinical complete response rates and increases organ preservation (OP) opportunities in rectal cancer, while its long-term impacts on quality of life (QoL) and anorectal function remain unclear. This study aimed to evaluate long-term QoL and anorectal function after iTNT, and to clarify how OP versus radical surgery affects patient-reported outcomes and functional recovery, providing evidence for individualized clinical decision-making. Material and methods: This prospective longitudinal cohort study enrolled rectal cancer patients receiving iTNT from 2021 to 2024. Patient-reported outcomes were dynamically evaluated using the EORTC QLQ-C30/CR29, Low Anterior Resection Syndrome (LARS), Wexner, and Memorial Sloan Kettering Cancer Center Bowel Function Instrument (MSKCC-BFI) questionnaires. Longitudinal changes were analyzed using linear mixed-effects models accounting for within-patient correlation. A separate conventional TNT cohort was included for exploratory cross-sectional comparison of long-term outcomes. Risk factors for major LARS were evaluated using univariable and multivariable logistic regression with multiple imputation and complete-case sensitivity analyses. Results: Of 172 patients receiving iTNT, 142 were eligible for QoL analysis and 137 for anorectal function assessment after excluding five patients with permanent stomas. Patients managed with OP were associated with better global health status, lower symptom burden, and better anorectal function than those undergoing total mesorectal excision (TME), with lower LARS and Wexner scores during follow-up. Compared with conventional TNT, poorer QoL and anorectal outcomes after iTNT were mainly observed in patients undergoing TME, whereas outcomes were largely comparable among those managed with OP. Multivariate analysis identified TME and shorter tumor distance from the anal verge as independent risk factors for major LARS. Conclusion: OP following iTNT was associated with more favorable long-term QoL and anorectal functional outcomes than TME. These findings support OP strategies as an important approach for optimizing long-term patient-reported outcomes in appropriately selected patients with rectal cancer.

Indexed as

Anorectal functionImmunotherapyOrgan preservationQuality of lifeRectal cancerTotal neoadjuvant therapy

Identifiers

PMID42733664
PMCPMC13571426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.